Nature Communications (Nov 2016)

Correction: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

  • Jacob J. Chabon,
  • Andrew D. Simmons,
  • Alexander F. Lovejoy,
  • Mohammad S. Esfahani,
  • Aaron M. Newman,
  • Henry J. Haringsma,
  • David M. Kurtz,
  • Henning Stehr,
  • Florian Scherer,
  • Chris A. Karlovich,
  • Thomas C. Harding,
  • Kathleen A. Durkin,
  • Gregory A. Otterson,
  • W. Thomas Purcell,
  • D. Ross Camidge,
  • Jonathan W. Goldman,
  • Lecia V. Sequist,
  • Zofia Piotrowska,
  • Heather A. Wakelee,
  • Joel W. Neal,
  • Ash A. Alizadeh,
  • Maximilian Diehn

DOI
https://doi.org/10.1038/ncomms13513
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 1

Abstract

Read online

Nature Communications 7: Article number: 11815 (2016); Published 10 June 2016; Updated 14 November 2016 Previous work by Del Re et al. describing the emergence of KRAS mutations following treatment of non-small cell lung cancer patients with EGFR tyrosine kinase inhibitors was inadvertently omitted from the reference list of this Article and should have been cited as follows.